AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05316935
Drug: Diane-35
RxNorm normalized name: Dianeal PD-2/2.5
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
Trial: NCT05316935
Drug: MET
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg po tid
Trial: NCT04161118
Drug: CTL019
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05378269
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen vaginal insert
Trial: NCT05292339
Drug: Triamcinolone injection to the shoulder, elbow, wrist, or hand
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
Trial: NCT05323058
Drug: Benzydamine Hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% topical oral spray
Trial: NCT00000659
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06326983
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
Trial: NCT06326983
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (0.1mg/kg given intravenously at induction of anesthesia)
Trial: NCT05654077
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Trial: NCT05792735
Drug: Cadonilimab Injection
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.
Trial: NCT04637282
Drug: PLX-200
RxNorm normalized name: PLX-PAD
DrugBank: PLX-PAD (DB17990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/mL oral solution of experimental drug
Trial: NCT06315790
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subcutaneously injections are given unilaterally in the face at predefined injection sites.
Trial: NCT06439277
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04959175
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
Trial: NCT04959175
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
Trial: NCT04959175
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
Trial: NCT05724693
Drug: Bemnifosbuvir (BEM)
RxNorm normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: A single dose of BEM will be administered
Trial: NCT04959175
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
Trial: NCT04882345
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
Trial: NCT05350956
Drug: TPO-RA (Herombopag)
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
Trial: NCT04959175
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
Trial: NCT05350956
Drug: TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)
RxNorm normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
Trial: NCT06572228
Drug: dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous (SC) injection
Trial: NCT04992858
Drug: CT053PTSA
RxNorm normalized name: Ct053ptsa free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT053PTSA will be administered orally once a day
Trial: NCT06566248
Drug: TQA3810 tablets+NUC
RxNorm normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
Trial: NCT06008119
Drug: Tunlametinib plus Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg BID Tunlametinib+720mg BID Vemurafenib
Trial: NCT00000724
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06008119
Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to investigators' suggestion
Trial: NCT06441747
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
Trial: NCT06441747
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
Trial: NCT05920941
Drug: [14C]JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
Trial: NCT05401058
Drug: Droperidol Injection
RxNorm normalized name: Droperidol Injection
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
Trial: NCT05401058
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
Trial: NCT05481957
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-10mg for 16 weeks
Trial: NCT05481957
Drug: valprote
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500\~1000mg for 16 weeks
Trial: NCT06568718
Drug: bovhyaluronidase azoximer
RxNorm normalized name: Bovhyaluronidase azoximer
DrugBank: Bovhyaluronidase azoximer (DB19020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
Trial: NCT06568718
Drug: tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4mg per os every day
Trial: NCT04404192
Drug: PH94B
RxNorm normalized name: PH94B
DrugBank: PH94B (DB04968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 100 microliters to each nostril 4 times a day
Trial: NCT05107128
Drug: SAGE-718
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules.
Trial: NCT05331859
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
Trial: NCT05331859
Drug: autologous serum (AS)
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
Trial: NCT05331859
Drug: conventional
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
Trial: NCT05935826
Drug: Essential Amino Acid Supplement by Amino Co
RxNorm normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
Trial: NCT05767879
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated.
Trial: NCT05925478
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Trial: NCT04698018
Drug: Faster Aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
Trial: NCT04698018
Drug: Novo Rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
Trial: NCT05145218
Drug: Anlotinib Hydrochloride Capsules
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Trial: NCT05145218
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is a novel anti-microtubule agent.
Trial: NCT00000679
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000679
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001113
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001113
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001113
Drug: Interferon alfa-n1
RxNorm normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05219513
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
Trial: NCT05219513
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
Trial: NCT05219513
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Trial: NCT06348134
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A chemotherapy drug.
Trial: NCT06475105
Drug: Oral Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Trial: NCT06348134
Drug: Pertuzumab Injection
RxNorm normalized name: pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Trial: NCT06348134
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A chemotherapy drug.
Trial: NCT06348134
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medication used to treat breast cancer.
Trial: NCT06348134
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medication used to treat breast cancer.
Trial: NCT06348134
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A hormone therapy drug.
Trial: NCT05401032
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral medication, once a day for 6 months.
Trial: NCT05546580
Drug: Iadademstat
RxNorm normalized name: Iadademstat
DrugBank: ORY-1001 (DB16848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iadademstat oral solution
Trial: NCT05546580
Drug: Gilteritinib Oral Tablet
RxNorm normalized name: gilteritinib Oral Tablet
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 120 mg Gilteritinib
Trial: NCT05795361
Drug: Idursulfase-IT
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
Trial: NCT05042128
Drug: LSTA1
RxNorm normalized name: LSTA1
DrugBank: LSTA1 (DB17346)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Trial: NCT05042128
Drug: Gemcitabine Injection
RxNorm normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Trial: NCT05042128
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Trial: NCT06297772
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine 20mg/m2 per day for consecutive 5 days
Trial: NCT06297772
Drug: Fludarabine Injection
RxNorm normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30mg/m2 per day for consecutive 5 days
Trial: NCT06297772
Drug: Busulfan Injection
RxNorm normalized name: busulfan Injection
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 3.2mg/kg per day for consecutive 4 days
Trial: NCT04119830
Drug: Rintatolimod
RxNorm normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05800600
Drug: Venofer
RxNorm normalized name: Venofer
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Trial: NCT06097975
Drug: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
Trial: NCT06097975
Drug: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
Trial: NCT06653738
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily per os for 3 years
Trial: NCT05046327
Drug: Avatrombopag 20 mg Oral Tablet
RxNorm normalized name: avatrombopag 20 MG Oral Tablet
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
Trial: NCT03935451
Drug: Apixaban 2.5 milligram
RxNorm normalized name: Product containing precisely apixaban 2.5 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days